{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:28:56Z","timestamp":1789194536194,"version":"build-2803163510"},"reference-count":85,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.jaad.2006.09.005","type":"journal-article","created":{"date-parts":[[2006,12,2]],"date-time":"2006-12-02T09:24:32Z","timestamp":1165051472000},"page":"317-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":181,"title":["Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management"],"prefix":"10.1016","volume":"56","author":[{"given":"Jenny C.","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parrish","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren C.","family":"Pinter-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharona","family":"Yashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin W.","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2006.09.005_bib1","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1610-0387.2005.05058.x","article-title":"The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies","volume":"3","author":"Segaert","year":"2005","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2006.09.005_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(04)01467-6","article-title":"Monoclonal antibodies as therapeutic agents for cancer","volume":"5","author":"Harris","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M","article-title":"Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system","volume":"92","author":"Goldstein","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2006.09.005_bib4","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1002\/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2","article-title":"The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer","volume":"71","author":"Mayer","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2006.09.005_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.09.005_bib6","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1093\/nar\/24.20.4050","article-title":"A 1.8 kb alternative transcript from the human\u00a0epidermal growth factor receptor gene encodes a truncated form of the receptor","volume":"24","author":"Reiter","year":"1996","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jaad.2006.09.005_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0014-5793(97)00412-2","article-title":"The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions","volume":"410","author":"Alroy","year":"1997","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jaad.2006.09.005_bib8","first-page":"25","article-title":"Biochemical and clinical implications of the ErbB\/HER signaling network of growth factor receptors","volume":"77","author":"Klapper","year":"2000","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.jaad.2006.09.005_bib9","first-page":"2958","article-title":"A novel approach in the treatment of\u00a0cancer: targeting the epidermal growth factor receptor","volume":"7","author":"Ciardiello","year":"2001","journal-title":"Clin\u00a0Cancer Res"},{"key":"10.1016\/j.jaad.2006.09.005_bib10","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer","volume":"21","author":"Mendelsohn","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib11","first-page":"3739","article-title":"Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells","volume":"6","author":"Ciardiello","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2006.09.005_bib12","unstructured":"Food and Drug Administration. Available from: http:\/\/www.fda.gov\/cder\/foi\/appletter\/2004\/125084ltr.pdf. Accessed April 4."},{"key":"10.1016\/j.jaad.2006.09.005_bib13","unstructured":"Food and Drug Administration. Available from: http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2006\/NEW01329.html. Accessed April 12, 2006."},{"key":"10.1016\/j.jaad.2006.09.005_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3816\/CLC.2006.n.009","article-title":"A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer","volume":"7","author":"Bogart","year":"2006","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jaad.2006.09.005_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1023\/A:1022928612511","article-title":"Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma","volume":"21","author":"Motzer","year":"2003","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jaad.2006.09.005_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-2407-5-131","article-title":"Randomized phase II\u2013study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer\u2013PARC: study protocol","volume":"5","author":"Krempien","year":"2005","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaad.2006.09.005_bib17","unstructured":"Food and Drug Administration. Available at: http:\/\/www.fda.gov\/bbs\/topics\/NEWS\/2006\/NEW01468.html. Accessed October 17, 2006."},{"key":"10.1016\/j.jaad.2006.09.005_bib18","unstructured":"Food and Drug Administration. Available from: http:\/\/www.fda.gov\/medwatch\/safety\/2005\/Nov_PI\/Tarceva2_PI.pdf. Accessed April 29, 2006."},{"key":"10.1016\/j.jaad.2006.09.005_bib19","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1200\/JCO.2005.16.584","article-title":"Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas","volume":"23","author":"Burris","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib20","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy","volume":"315","author":"Arora","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaad.2006.09.005_bib21","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/annonc\/mdj084","article-title":"Cetuximab and irinotecan\/5-fluorouracil\/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma","volume":"17","author":"Folprecht","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib23","doi-asserted-by":"crossref","first-page":"8646","DOI":"10.1200\/JCO.2005.02.4646","article-title":"Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic\/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study","volume":"23","author":"Burtness","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib24","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the\u00a0antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000088502","article-title":"Cetuximab-induced acne","volume":"211","author":"Molinari","year":"2005","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2006.09.005_bib26","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1067\/mjd.2002.124621","article-title":"Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody","volume":"47","author":"Boucher","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib27","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1200\/JCO.2004.02.168","article-title":"Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer","volume":"22","author":"Chang","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000073100","article-title":"Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor","volume":"207","author":"Dainichi","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2006.09.005_bib29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1346-8138.2003.tb00387.x","article-title":"Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor","volume":"30","author":"Nakano","year":"2003","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib30","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/annonc\/mdi300","article-title":"Trichomegaly of the eyelashes following treatment with cetuximab","volume":"16","author":"Bouche","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/02841860310006038","article-title":"Epidermal growth factor receptor inhibition induces trichomegaly","volume":"42","author":"Dueland","year":"2003","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib32","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3816\/CLC.2003.n.016","article-title":"Dermatologic side effects associated with gefitinib therapy: clinical experience and management","volume":"4","author":"Herbst","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jaad.2006.09.005_bib33","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib34","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","article-title":"Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin","volume":"18","author":"Baselga","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib35","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1200\/JCO.2005.07.119","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib36","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","article-title":"Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining?","volume":"23","author":"Perez-Soler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib37","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jaad.2005.08.033","article-title":"An acneiform eruption due to erlotinib: prognostic implications and management","volume":"54","author":"Journagan","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JCO.2005.02.5825","article-title":"First-line single agent treatment with gefitinib in patients with\u00a0advanced non-small-cell lung cancer: a phase II study","volume":"24","author":"Niho","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib39","first-page":"569","article-title":"Acneiform eruption induced by Iressa (gefitinib) tablets used to treat non-small cell lung cancer","volume":"3","author":"Warthan","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib40","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2006.09.005_bib41","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1158\/1078-0432.CCR-05-0790","article-title":"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen","volume":"11","author":"Johnson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2006.09.005_bib42","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non\u2013small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib44","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1200\/JCO.2004.00.1438","article-title":"Phase I\/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer","volume":"23","author":"Robert","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib45","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types","volume":"20","author":"Baselga","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib46","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib47","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1200\/JCO.2001.19.13.3234","article-title":"Phase I study of anti\u2013epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer","volume":"19","author":"Robert","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib48","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archderm.138.1.129","article-title":"Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors","volume":"138","author":"Kimyai-Asadi","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib49","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1365-2133.2005.06835.x","article-title":"Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy","volume":"153","author":"Gutzmer","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib50","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ctrv.2003.10.003","article-title":"Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation","volume":"30","author":"Thomas","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jaad.2006.09.005_bib51","first-page":"119","article-title":"Acneiform eruption due to \u201cmegadose\u201d vitamins B6 and B12","volume":"48","author":"Sherertz","year":"1991","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2006.09.005_bib52","first-page":"238","article-title":"Acneiform eruption induced by epidermal growth factor\u00a0receptor inhibitors in patients with solid tumours","volume":"151","author":"Jacot","year":"2004","journal-title":"Br\u00a0J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib53","unstructured":"National Cancer Institute. Common Toxicity Criteria. Available from: http:\/\/ctep.cancer.gov\/forms\/CTCv20_4-30-992.pdf. Accessed November 13, 2005."},{"key":"10.1016\/j.jaad.2006.09.005_bib54","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0. Available from: http:\/\/ctep.cancer.gov\/forms\/CTCAEv3.pdf. Accessed November 13, 2005."},{"key":"10.1016\/j.jaad.2006.09.005_bib55","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1046\/j.1365-2133.2002.04864.x","article-title":"Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor","volume":"147","author":"Van Doorn","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib56","first-page":"2478","article-title":"Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients","volume":"9","author":"Malik","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2006.09.005_bib57","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2002.20.1.110","article-title":"Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition","volume":"20","author":"Albanell","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib58","first-page":"1943","article-title":"Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors","volume":"3","author":"Fan","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2006.09.005_bib59","first-page":"4322","article-title":"Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies","volume":"53","author":"Fan","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2006.09.005_bib60","first-page":"3666","article-title":"Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145","volume":"56","author":"Peng","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2006.09.005_bib61","first-page":"1397","article-title":"Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody","volume":"12","author":"Wu","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.jaad.2006.09.005_bib62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0092-8674(94)90573-8","article-title":"p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21","volume":"78","author":"Toyoshima","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2006.09.005_bib63","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/1523-1747.ep12263298","article-title":"Distribution of epidermal growth factor receptors in rat tissues during embryonic skin development, hair formation, and the adult hair growth cycle","volume":"83","author":"Green","year":"1984","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/1523-1747.ep12276708","article-title":"Differences in human skin between the epidermal growth factor receptor distribution detected by EGF binding and monoclonal antibody recognition","volume":"85","author":"Green","year":"1985","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib65","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/1523-1747.ep12264708","article-title":"Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages","volume":"83","author":"Nanney","year":"1984","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib66","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/1523-1747.ep12874601","article-title":"Immunolocalization of epidermal growth factor receptors in normal developing human skin","volume":"94","author":"Nanney","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib67","first-page":"786","article-title":"Epidermal growth factor, estrogen, and progesterone receptor expression in primary sweat gland carcinomas and primary and metastatic mammary carcinomas","volume":"12","author":"Busam","year":"1999","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jaad.2006.09.005_bib68","first-page":"505","article-title":"The EGF receptor\u2013an essential regulator of multiple epidermal functions","volume":"10","author":"Jost","year":"2000","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib69","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1101\/gad.5.5.714","article-title":"Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation","volume":"5","author":"Vassar","year":"1991","journal-title":"Genes Dev"},{"key":"10.1016\/j.jaad.2006.09.005_bib70","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0092-8674(93)90227-H","article-title":"Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation","volume":"73","author":"Mann","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2006.09.005_bib71","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/376337a0","article-title":"Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor","volume":"376","author":"Miettinen","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2006.09.005_bib72","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1002\/j.1460-2075.1995.tb00206.x","article-title":"Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure","volume":"14","author":"Murillas","year":"1995","journal-title":"EMBO J"},{"key":"10.1016\/j.jaad.2006.09.005_bib73","first-page":"1959","article-title":"Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development","volume":"150","author":"Hansen","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2006.09.005_bib74","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0002-9440(10)63654-1","article-title":"Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation","volume":"163","author":"Mascia","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2006.09.005_bib75","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1056\/NEJMicm050560","article-title":"Images in clinical medicine. Cetuximab-associated acneiform eruption","volume":"353","author":"Moss","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.09.005_bib76","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0190-9622(84)80289-3","article-title":"Paronychia and pyogenic granuloma-like lesions with isotretinoin","volume":"10","author":"Blumental","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib77","first-page":"165","article-title":"Pseudotumor cerebri after treatment with tetracycline and isotretinoin for acne","volume":"55","author":"Lee","year":"1995","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2006.09.005_bib78","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2005.07010.x","article-title":"Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab","volume":"154","author":"Suh","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib79","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/00015550310005898","article-title":"Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor","volume":"84","author":"Lee","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2006.09.005_bib80","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.2005.04.057","article-title":"Practical management of patients with non-small-cell lung cancer treated with gefitinib","volume":"23","author":"Shah","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2006.09.005_bib81","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0092-8674(90)90073-N","article-title":"Identification of a major keratinocyte cell envelope protein, loricrin","volume":"61","author":"Mehrel","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2006.09.005_bib82","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1242\/jcs.107.2.693","article-title":"Protein composition of cornified cell envelopes of epidermal keratinocytes","volume":"107","author":"Steven","year":"1994","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jaad.2006.09.005_bib83","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/1523-1747.ep12470383","article-title":"Evidence that the corneocyte has a chemically bound lipid envelope","volume":"88","author":"Swartzendruber","year":"1987","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2006.09.005_bib84","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1126\/science.7618084","article-title":"Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype","volume":"269","author":"Threadgill","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.jaad.2006.09.005_bib85","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1534\/genetics.166.1.331","article-title":"Velvet,\u00a0a dominant Egfr mutation that causes wavy hair and defective eyelid development in mice","volume":"166","author":"Du","year":"2004","journal-title":"Genetics"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096220602531X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096220602531X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:06:47Z","timestamp":1759270007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096220602531X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":85,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S019096220602531X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2006.09.005","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1089451.544696","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and management","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2006.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}